• Layla Saliba, Pierre Mondoly, Alexandre Duparc, Alessandra Bura-Rivière, Philippe Maury, Violaine Calmels, Brigitte Sallerin, Atul Pathak, Jean-Louis Montastruc, and Haleh Bagheri.
• Service de Pharmacologie Médicale et Clinique, Centre Midi-Pyrénées de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
• Therapie. 2015 Nov 1; 70 (6): 485-92.

ObjectiveDescribing the factors associated with direct oral anticoagulants (DOA) prescription in patients with atrial fibrillation (AF).MethodThis study was performed in Toulouse on a cohort of patients received in rhythmology consultation, treated with vitamin K antagonists (VKA) or DOA for AF. A multivariate model was performed using logistic regression to describe the factors associated with DOA prescription and secondly, those associated with discontinuation of the anticoagulant.ResultsAmong the 140 patients included, 96 (66%) were treated with VKA and 48 (34%) with DOA. Recent AF diagnosis (OR 7.52, 95% CI [2.41;23.29], p = 0.001), previous exposure to VKA (OR 17.11, 95% CI [4.48;60.91], p<0.001), and no current exposure to anti-platelet agents (APA) (OR 7.69, 95% CI [1.22; 50.00], p = 0.030) were associated to DOA prescription. Discontinuation of the anticoagulant (n=24) was associated to DOA intake (OR 2.71, 95% CI [1.21; 6.08], p = 0.016).DiscussionDOA are less prescribed than VKA in patients treated with APA. DOA switch to VKA was not systematic in patients diagnosed for a long time. However, international normalized ratio (INR) values were stable in most of patients treated with VKA at the switching to DOA. A more powerful study would confirm the factors associated with DOA prescription.© 2015 Société Française de Pharmacologie et de Thérapeutique.

63 keywords...

hide…